Elicio Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELTX research report →
Range $1.5 – $17
Price Chart
About the company
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers.
- CEO
- Robert T. Connelly
- IPO
- 2021
- Employees
- 33
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on ELTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $36.63M
- P/E
- -0.90
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 4.66
- EV/EBITDA
- -0.67
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1266.43%
- ROIC
- -163.43%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,128,000+4.2%
- Op Income
- $-37,714,000
- Net Income
- $-39,571,000+23.8%
- EPS
- $-2.58+39.3%
- OCF Growth
- +0.3%
- FCF Growth
- +0.5%
- 52W High
- $16.00
- 52W Low
- $1.71
- 50D MA
- $2.55
- 200D MA
- $7.37
- Beta
- 1.86
- RSI (14)
- 33
- Avg Volume
- 434.07K
No earnings-call transcripts are available for ELTX yet.
- Free Float
- 46.6%
- Shares Outstanding
- 19.07M
- Float Shares
- 8.88M
of shares held by institutions
53 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Knoll Capital Management, LLC | 1.21M | ▲ 581.04K |
| Blackrock, Inc. | 766.00K | ▲ 715.41K |
| Vanguard Capital Management LLC | 572.15K | ▲ 53.51K |
| Vanguard Group Inc | 496.90K | ▲ 23.04K |
| Geode Capital Management, LLC | 311.35K | ▲ 176.19K |
| State Street Corp | 179.42K | ▲ 128.80K |
| Northern Trust Corp | 130.16K | ▲ 70.43K |
| Ikarian Capital, LLC | 100.00K | ▲ 100.00K |
| Vanguard Portfolio Management LLC | 88.91K | ▲ 88.91K |
| Vanguard Fiduciary Trust Co | 88.06K | ▲ 18.87K |
| Alliancebernstein L.P. | 81.28K | ▲ 81.28K |
| Ubs Group AG | 40.42K | ▲ 6.65K |
Held by 64 ETFs
Biggest fund positions in ELTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 31, 26 | ADAMS JULIAN | other | 21,750 |
| Aug 31, 26 | Ashe Carol Gail | other | 21,750 |
| Aug 31, 26 | Chudnovsky Yekaterina | other | 21,750 |
| Aug 31, 26 | Nissenson Allen | other | 21,750 |
| Aug 31, 26 | RUFFOLO ROBERT R | other | 21,750 |
| Aug 31, 26 | WILSON KAREN J | other | 21,750 |
| Aug 31, 26 | Venkatesan Jay | other | 21,750 |
| Jul 16, 26 | Haqq Christopher | other | 64,643 |
| Jul 16, 26 | DeMuth Peter | other | 52,832 |
| Jul 16, 26 | Shah Preetam | other | 60,833 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ELTX coverage
Recent articles, reports, and earnings notes.
No research on ELTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ELTX report →Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
globenewswire.com · Sep 24
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Aug 31
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
globenewswire.com · Aug 24
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com · Aug 13
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
prnewswire.com · Jul 9
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
globenewswire.com · Jul 7
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
globenewswire.com · Jul 6
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
globenewswire.com · Jul 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.